SEC Form D · Amendment · filed August 31, 2020
Kinnate Biopharma Inc
Rule 506(b): private placement to accredited investors, no public advertising.
People & firms on this filing (25)
Keith W. Flaherty · San Diego, CADirectorNima W. Farzan · San Diego, CAExec · DirectorCarl W. Gordon · San Diego, CADirectorMichael W. Rome · San Diego, CADirectorStephen W. Kaldor · San Diego, CADirector · PromoterJim W. Tananbaum · San Diego, CADirectorMark W. Meltz · San Diego, CAExecFloyd E. Wilson Iii · Mill Valley, CADirectorHarbert Management Corporation · BIRMINGHAM, ALDirector · PromoterDax Vlassis · NEW YORK, NYExec · DirectorMark Mennitt · Greenwich, CTDirectorSarah Sullivan · Mill Valley, CADirectorHarbert Fund Advisors, Inc · BIRMINGHAM, ALExecHarbert Stoneview Fund GP, LLC · BIRMINGHAM, ALDirectorDean W. Mitchell · San Diego, CADirectorLaurie W. Smaldone Alsup · San Diego, CADirectorKarim Faris · Atlanta, GADirectorTed Schlein · Atlanta, GAExecRyan Barretto · Atlanta, GADirectorRon Shah · Atlanta, GADirector · PromoterTerrapin Asset Management, LLC · Miami, FLDirectorTerrapin Realization GP, LLC · Miami, FLDirectorEricka Z. Iachello · New York, NYExec · DirectorDean W. Mitchell · San Diego, CADirectorLaurie W. Smaldone Alsup · San Diego, CADirector Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗